Home Cart Sign in  
Chemical Structure| 14259-45-1 Chemical Structure| 14259-45-1

Structure of Asperuloside
CAS No.: 14259-45-1

Chemical Structure| 14259-45-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Asperuloside is an iridoid monoterpenoid glycoside with anti-inflammatory properties.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Asperuloside

CAS No. :14259-45-1
Formula : C18H22O11
M.W : 414.36
SMILES Code : O=C1O[C@]2([H])[C@@]3([H])[C@](C(COC(C)=O)=C2)([H])[C@H](O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)OC=C13
MDL No. :MFCD02094172

Safety of Asperuloside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
NCI-H716 cells 100μM 30 min and 6 h To evaluate the effect of ASP on GLP-1 secretion, results showed that ASP did not directly stimulate GLP-1 secretion. PMC7498753
Bone marrow-derived macrophages (BMMs) 0.1, 0.2, 0.4 mM 5 days To evaluate the effect of ASP on RANKL-induced osteoclast differentiation. Results showed that ASP dose-dependently reduced the number and size of osteoclasts. PMC9412302
HRVEC cells 200 μg/mL 1 h To assess the effect of ASPA on LPS-induced changes in cell connectivity proteins in HRVECs. ASPA reversed the LPS-induced downregulation of ZO-1 and VE-cadherin. PMC11746008
ARPE-19 cells 200 μg/mL 1 h To evaluate the inhibitory effect of ASPA on LPS-induced inflammation in RPE cells. ASPA significantly reduced the mRNA and protein levels of ICAM-1, IL-6, MCP-1, and TNF-α induced by LPS. PMC11746008
RAW 264.7 macrophages 40, 80, 160 μg/mL 1 h Significantly reduced levels of NO, PGE2, TNF-α, and IL-6, inhibited iNOS and COX-2 mRNA and protein expression, exerted anti-inflammatory effects by suppressing NF-κB and MAPK signaling pathways PMC6073666

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice High-fat diet-induced obesity and type 2 diabetes model Oral 0.25% w/w 12 weeks To evaluate the effect of ASP on obesity and type 2 diabetes, results showed that ASP improved obesity and type 2 diabetes by modulating gut microbiota and metabolic signaling. PMC7498753
Sprague-Dawley rats Ligature-induced peri-implantitis model Intraperitoneal injection 20 and 40 mg/kg Every second day for a total of 14 injections To evaluate the effect of ASP on preventing peri-implantitis. Results showed that ASP delayed the onset time, reduced the morbidity, and decreased alveolar bone resorption around the implant. PMC9412302
Mice High-fat diet-induced obesity model Oral 3 mg/day Once daily for 12 weeks To investigate the effects of Asperuloside on body weight, food intake, fat content, blood glucose, and insulin levels in high-fat diet-fed mice. Results showed that Asperuloside significantly reduced body weight (-10.5%) and food intake (-12.8%) in HFD-fed mice, decreased visceral fat mass (-35%), and lowered fasting blood glucose (-16%) and plasma insulin levels (-29%). PMC8076851
Sprague Dawley rats Cadmium-induced nephrocardiac toxicity model Oral gavage 50 mg/kg Once daily for 5 weeks To investigate the protective effects of asperuloside (ASP) against cadmium-induced nephrocardiac toxicity. The results showed that ASP significantly decreased Cd-instigated oxidative stress, serum BUN, Scr, AST, CK-MB, TnT and LDH levels, as well as histopathological alterations. Furthermore, ASP notably attenuated Cd-induced cardiorenal apoptosis and fibrosis by reducing caspase 3 and TGF-β levels, decreasing the stain intensity of α-SMA and collagen IV, while increasing Bcl2 intensity. PMC10081990
Sprague Dawley rats Endotoxin-induced uveitis (EIU) model Intravitreal injection 500 ng/eye Single injection, lasting 24 hours To evaluate the anti-inflammatory effect of ASPA in EIU rats. ASPA significantly alleviated clinical symptoms of EIU, reduced inflammatory cell infiltration, and decreased the expression of inflammatory mediators (ICAM-1, IL-6, MCP-1, and TNF-α). PMC11746008

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.07mL

2.41mL

1.21mL

24.13mL

4.83mL

2.41mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories